SynthesisJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2021
Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review.
Synthesis in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- Urinary Tract Infections: Etiology and Emerging Therapeutic Approaches.Antibiotics (Basel, Switzerland) · 2026Review
- ΔJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Cannabidiol in Neurology: Current Insights and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploring the effects of cannabidiol encapsulation in liposomes on their physicochemical properties and biocompatibility.Drug delivery · 2025Article
- Immunomodulatory Effects of a High-CBD Cannabis Extract: A Comparative Analysis with Conventional Therapies for Oral Lichen Planus and Graft-Versus-Host Disease.International journal of molecular sciences · 2025Article
- ABCB1 polymorphisms are associated with clinical response to nabiximols in patients with multiple sclerosis-related spasticity.Journal of cannabis research · 2025Article
- Exploring the interconnected properties of cannabidiol suspensions and orodispersible films.Scientific reports · 2025Article
- Beyond conventional care: exploring complementary and alternative medicine for autoimmune disorders.Reumatologia · 2025Review
- Evaluation of the Efficacy of a Full-Spectrum Low-THCBiomolecules · 2024Article
- Review
- Non-linear plasma protein binding of cannabidiol.Journal of cannabis research · 2024Article
- Feature-Based Molecular Network-Assisted Cannabinoid and Flavonoid Profiling ofAntioxidants (Basel, Switzerland) · 2024Article
- Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.Pharmaceutics · 2024Review
- Cannabidiol exerts multitarget immunomodulatory effects on PBMCs from individuals with psoriasis vulgaris.Frontiers in immunology · 2024Article
- Immunomodulatory Plant Natural Products as Therapeutics against Inflammatory Skin Diseases.Current topics in medicinal chemistry · 2024Review
- Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.Therapeutic advances in vaccines and immunotherapy · 2024Article
- Effect of Cannabidiol on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.International journal of molecular sciences · 2023Article
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the most common chronic autoimmune disease of the central nervous system. Efficacy of treatments for MS is associated with risk of adverse effects, and effective and well-tolerated drugs remain a major unmet need. Cannabis (Cannabis sativa L., fam. Cannabaceae) and cannabinoids are popular among MS patients to treat spasticity and pain. Cannabinoids are endowed with remarkable immunomodulating properties, and in particular the non-psychotropic cannabinoid cannabidiol (CBD) is increasingly recognized as anti-inflammatory and immunosuppressive, nevertheless with excellent tolerability even at high doses. In this systematic review, we retrieved and critically evaluated available evidence regarding the immune and disease-modifying effects of CBD in experimental autoimmune encephalomyelitis (EAE) and in MS. Evidence in rodent models of EAE strongly supports CBD as effective, while clinical evidence is still limited and usually negative, due to paucity of studies and possibly to the use of suboptimal dosing regimens. Better characterization of targets acted upon by CBD in MS should be obtained in ex vivo/in vitro studies in human immune cells, and higher doses should be tested in well-designed clinical trials with clinically relevant efficacy endpoints. Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.